For type 2 diabetes mellitus. Sold as Soliqua 100/33. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 1 application for Insulin glargine; Lixisenatide (sold as Soliqua 100/33), first approved Nov 21, 2016, with 1 new use approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 21, 2016 | Soliqua 100/33BLA 208673 · New combination | sanofi-aventis US | 11 | Marketed |
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Soliqua 100-33 | Part D | $275M | −8% | 53,834 |
Of the 5 whose ending is known, 100% met their primary endpoint, 0% missed it and 0% stopped early.
| Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral AgentsType 2 Diabetes · Shanghai Zhongshan Hospital | Phase 4 | Recruiting | Dec 29, 2025 |
| Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 DiabetesType 2 Diabetes · Yanbing Li | Phase 4 | Not yet recruiting | Sep 15, 2025 |
| Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced DiabetesSteroid-Induced Diabetes, Steroid-Induced Hyperglycemia · Medical University of Warsaw | Phase 4 | Enrolling by invitation | Aug 12, 2025 |
| iGlarLixi CGM Study in Chinese T2D Individuals After OADsType 2 Diabetes (T2D) · Sanofi | Phase 4 | Recruiting | Nov 4, 2024 |
| Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyCardiovascular Events, Type2 Diabetes · Brigham and Women's Hospital | — | Active, not recruiting | Feb 2, 2022 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA